London, UK – [15/05/2025] – ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines across Europe, Canada, and Australia, today announced the expansion of its existing partnership with PHARMATHEN, a leading pharmaceutical company specialized in the development and manufacturing of long-acting injectable therapies (LAIs).
Under the terms of this exclusive license and supply agreement, ADVANZ PHARMA secures exclusive commercialization rights to a long-acting injectable specialty medicine in selected countries throughout Europe, including the UK, as well as in Australia. ADVANZ PHARMA will manage registration, commercialization, and market access activities, while PHARMATHEN is responsible for the product’s development and manufacturing.
This agreement marks a significant milestone in ADVANZ PHARMA’s and PHARMATHEN's strategic commitment to enhancing patient access to specialty medicines, expanding therapeutic choices, and addressing unmet clinical needs in collaboration with healthcare professionals.
About ADVANZ PHARMA
Partner of choice in specialty, hospital, and rare disease medicines
ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.
For more information, please visit our Website or LinkedIn.
For media inquiries, please contact:
Courtney Baines
ADVANZ PHARMA
Email: courtney.baines@advanzpharma.com
About PHARMATHEN
PHARMATHEN is a company headquartered in Greece with a strategic focus on the development of specialty and niche injectable products. Pharmathen is a global leader in the development, manufacturing, and supply of long-acting injectable products based on its proprietary technology platforms. With its unwavering commitment to patients and acute focus on enhancing access of long-acting injectables products, PHARMATHEN offers one of the most comprehensive under-development and commercially available portfolio of long-acting injectable products globally.
For more information, please visit our Website or LinkedIn.
For media inquiries, please contact:
Natasha Kyriakaki
PHARMATHEN
Email: nkyriakaki@pharmathen.com
